A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

doi:10.1038/nature10937

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Nature - 18 Mar 2012

Chen Zhao, Cheng Katherine, Walton Zandra, Wang Yuchuan, Ebi Hiromichi, Shimamura Takeshi, Liu Yan, Tupper Tanya, Ouyang Jing, Li Jie, Gao Peng, Woo Michele S, Xu Chunxiao, Yanagita Masahiko, Altabef Abigail, Wang Shumei, Lee Charles, Nakada Yuji, Peña Christopher G, Sun Yanping, Franchetti Yoko, Yao Catherine, Saur Amy, Cameron Michael D, Nishino Mizuki, Hayes D Neil, Wilkerson Matthew D, Roberts Patrick J, Lee Carrie B, Bardeesy Nabeel, Butaney Mohit, Chirieac Lucian R, Costa Daniel B, Jackman David, Sharpless Norman E, Castrillon Diego H, Demetri George D, Jänne Pasi A, Pandolfi Pier Paolo, Cantley Lewis C, Kung Andrew L, Engelman Jeffrey A, Wong Kwok-Kin

Abstract excerpt

Targeted therapies have demonstrated efficacy against specific subsets of molecularly defined cancers. Although most patients with lung cancer are stratified according to a single oncogenic driver, cancers harbouring identical activating genetic mutations show large variations in their responses to the same targeted therapy. The biology underlying this heterogeneity is not well understood, and the impact of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Clinical Trials, Phase II as Topic

Share to Docetaxel

Share to Drug Evaluation, Preclinical

Share to Fluorodeoxyglucose F18

Share to Mitogen-Activated Protein Kinase Kinases

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 22425996
DOI: 10.1038/nature10937
PMCID: PMC3385933

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.PMID 22425996Read ↗

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.Semantic proximity Read ↗

RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Semantic proximity Read ↗

The APL paradigm and the "co-clinical trial" project.Semantic proximity Read ↗

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.Semantic proximity Read ↗

Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial OutcomesSemantic proximity Read ↗

Novel Kras -mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burdenSemantic proximity Read ↗

Mouse hospital and co-clinical trial project--from bench to bedside.Semantic proximity Read ↗

The National Lung Matrix Trial of personalized therapy in lung cancer.Semantic proximity Read ↗

Genetic determinants of EGFR -Driven Lung Cancer Growth and Therapeutic Response In VivoSemantic proximity Read ↗

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.Semantic proximity Read ↗

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.Semantic proximity Read ↗

Phenotype-dependent subtyping exposes high MYC activity as a targetable dependency in LuAdSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.